

Jens Wiltfang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7895436/publications.pdf>

Version: 2024-02-01

419
papers

26,269
citations

10984

71
h-index

9342

143
g-index

461
all docs

461
docs citations

461
times ranked

26928
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1088-1093.	21.4	2,697
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
3	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	21.4	1,708
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
5	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
6	Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 1998, 43, 32-40.	5.3	456
7	The mechanism of β -Secretase dysfunction in familial Alzheimer disease. <i>EMBO Journal</i> , 2012, 31, 2261-2274.	7.8	432
8	Presenilin clinical mutations can affect β -secretase activity by different mechanisms. <i>Journal of Neurochemistry</i> , 2006, 96, 732-742.	3.9	387
9	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e13950.	2.5	347
10	Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Neuroscience Letters</i> , 1997, 225, 210-212.	2.1	332
11	Therapeutic approaches to Alzheimer's disease. <i>Brain</i> , 2006, 129, 2840-2855.	7.6	310
12	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	7.6	284
13	Neurochemical diagnosis of Alzheimer's dementia by CSF A β ₄₂ , A β ₄₂ /A β ₄₀ ratio and total tau. <i>Neurobiology of Aging</i> , 2004, 25, 273-281.	3.1	267
14	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016, 21, 108-117.	7.9	260
15	Highly conserved and disease-specific patterns of carboxyterminally truncated A β peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. <i>Journal of Neurochemistry</i> , 2002, 81, 481-496.	3.9	240
16	Amyloid β peptide ratio 42/40 but not A β ₄₂ correlates with phospho-tau in patients with low- and high-CSF A β ₄₀ load. <i>Journal of Neurochemistry</i> , 2007, 101, 1053-1059.	3.9	237
17	β -Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer's Disease. <i>Science</i> , 2009, 324, 639-642.	12.6	233
18	Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. <i>Annals of Neurology</i> , 2001, 50, 150-156.	5.3	229

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
20	Identification of New Functional Inhibitors of Acid Sphingomyelinase Using a Structure-Property-Activity Relation Model. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 219-237.	6.4	203
21	CSF amyloid- β -peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. <i>Brain</i> , 2006, 129, 1177-1187.	7.6	193
22	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. <i>Lancet Neurology</i> , The, 2013, 12, 233-243.	10.2	177
23	Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. <i>NeuroImage</i> , 2013, 83, 472-484.	4.2	157
24	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. <i>Molecular Psychiatry</i> , 2010, 15, 138-145.	7.9	156
25	Flavonoids as Therapeutic Compounds Targeting Key Proteins Involved in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2014, 5, 83-92.	3.5	151
26	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
27	Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides. <i>Clinical Chemistry</i> , 2006, 52, 332-334.	3.2	139
28	Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric, and electroencephalographic investigations. <i>Hepatology</i> , 1998, 28, 1215-1225.	7.3	138
29	Improved electrophoretic separation and immunoblotting of beta-amyloid ($A\beta$) peptides 1-40, 1-42, and 1-43. <i>Electrophoresis</i> , 1997, 18, 527-532.	2.4	133
30	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
31	Persistence of Haloperidol in Human Brain Tissue. <i>American Journal of Psychiatry</i> , 1999, 156, 885-890.	7.2	131
32	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 15.	6.2	131
33	High activity of acid sphingomyelinase in major depression. <i>Journal of Neural Transmission</i> , 2005, 112, 1583-1590.	2.8	126
34	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	3.1	125
35	Combined CSF tau, p-tau181 and amyloid- β 38/40/42 for diagnosing Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2009, 116, 203-212.	2.8	124
36	Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. <i>Molecular Neurodegeneration</i> , 2010, 5, 40.	10.8	124

#	ARTICLE	IF	CITATIONS
37	Disentangling Structural Brain Alterations Associated With Violent Behavior From Those Associated With Substance Use Disorders. <i>Archives of General Psychiatry</i> , 2011, 68, 1039.	12.3	116
38	Elevation of β -Amyloid Peptide 2 β 42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 42645-42657.	3.4	115
39	Beta-Amyloid 1 β 42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 200-208.	1.5	114
40	Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. <i>Acta Neuropathologica Communications</i> , 2018, 6, 108.	5.2	107
41	The amyloid β (A β) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated A β peptide. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 1291-1296.	1.5	106
42	Electrophoretic Separation of β A4 Peptides (1 β 40) and (1 β 42). <i>Analytical Biochemistry</i> , 1996, 237, 24-29.	2.4	105
43	Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 69-84.	2.6	105
44	Blue light improves cognitive performance. <i>Journal of Neural Transmission</i> , 2007, 114, 457-460.	2.8	104
45	Presenilin-1 L166P Mutant Human Pluripotent Stem Cell-Derived Neurons Exhibit Partial Loss of β -Secretase Activity in Endogenous Amyloid- β Generation. <i>American Journal of Pathology</i> , 2012, 180, 2404-2416.	3.8	104
46	Glutamate and the glutamate receptor system: a target for drug action. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, S33-S40.	2.7	103
47	International quality control survey of neurochemical dementia diagnostics. <i>Neuroscience Letters</i> , 2006, 409, 1-4.	2.1	102
48	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2017, 22, 153-160.	7.9	102
49	Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects. <i>NeuroImage</i> , 2014, 101, 390-403.	4.2	99
50	Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. <i>Journal of Neurochemistry</i> , 2005, 94, 289-298.	3.9	98
51	Flupirtine shows functional NMDA receptor antagonism by enhancing Mg ²⁺ block via activation of voltage independent potassium channels. <i>Journal of Neural Transmission</i> , 1999, 106, 857-867.	2.8	97
52	Tau Protein Phosphorylated at Threonine 181 in CSF as a Neurochemical Biomarker in Alzheimer's Disease: Original Data and Review of the Literature. <i>Journal of Molecular Neuroscience</i> , 2004, 23, 115-122.	2.3	97
53	Amyloid- β -Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease. <i>Analytical Chemistry</i> , 2016, 88, 2755-2762.	6.5	97
54	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97

#	ARTICLE	IF	CITATIONS
55	Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study. <i>BMJ: British Medical Journal</i> , 1998, 316, 577-582.	2.3	94
56	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	3.1	94
57	Polymeric Complements to the Alzheimer's Disease Biomarker β -Amyloid Isoforms $A\beta^{1-40}$ and $A\beta^{1-42}$ for Blood Serum Analysis under Denaturing Conditions. <i>Journal of the American Chemical Society</i> , 2011, 133, 9220-9223.	13.7	93
58	Isoform Pattern of 14-3-3 Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease. <i>Journal of Neurochemistry</i> , 2002, 73, 2485-2490.	3.9	92
59	A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100 000-1000, and their detection with picomolar sensitivity. <i>Electrophoresis</i> , 1991, 12, 352-366.	2.4	91
60	Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid β peptides. <i>Electrophoresis</i> , 2004, 25, 2912-2918.	2.4	90
61	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 404-417.	1.5	90
62	PolyGP in cerebrospinal fluid links <i>C9orf72</i> -associated dipeptide repeat expression to the asymptomatic phase of <i>ALS</i> / <i>FTD</i> . <i>EMBO Molecular Medicine</i> , 2017, 9, 859-868.	6.9	90
63	Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. <i>Biological Psychiatry</i> , 2004, 55, 524-530.	1.3	86
64	Validation of amyloid- β peptides in CSF diagnosis of neurodegenerative dementias. <i>Molecular Psychiatry</i> , 2007, 12, 671-680.	7.9	85
65	Serum neurofilament light chain in behavioral variant frontotemporal dementia. <i>Neurology</i> , 2018, 91, e1390-e1401.	1.1	85
66	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.2	85
67	Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. <i>Neuroscience Letters</i> , 2004, 370, 36-39.	2.1	83
68	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	7.6	83
69	β -Amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 2003, 54, 263-267.	5.3	82
70	Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. <i>Journal of Neural Transmission</i> , 2009, 116, 1163-1167.	2.8	80
71	Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 1180-1186.	2.0	79
72	Non-Drug Therapies for Dementia: An Overview of the Current Situation with Regard to Proof of Effectiveness. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 115-125.	1.5	78

#	ARTICLE	IF	CITATIONS
73	Tau Protein, A β ²⁴² and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 164-170.	1.5	75
74	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 939-950.	2.6	74
75	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 66.	6.2	74
76	A combined miRNA&piRNA signature to detect Alzheimer&TM's disease. <i>Translational Psychiatry</i> , 2019, 9, 250.	4.8	74
77	Free water elimination improves test&retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects. <i>Human Brain Mapping</i> , 2017, 38, 12-26.	3.6	72
78	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. <i>Neurology</i> , 2021, 96, .	1.1	72
79	Independent Generation of A β ²⁴² and A β ²³⁸ Peptide Species by β ³ -Secretase. <i>Journal of Biological Chemistry</i> , 2008, 283, 17049-17054.	3.4	70
80	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt&Jacob disease. <i>Neurobiology of Aging</i> , 2006, 27, 10-15.	3.1	69
81	Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. <i>Epilepsy Research</i> , 1999, 36, 75-82.	1.6	68
82	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. <i>PLoS ONE</i> , 2018, 13, e0197329.	2.5	68
83	Cerebrospinal fluid&E-optimized two&E-dimensional difference gel electrophoresis (2&E DIGE) facilitates the differential diagnosis of Creutzfeldt&Jacob disease. <i>Proteomics</i> , 2008, 8, 4357-4366.	2.2	66
84	Total tau protein, phosphorylated tau (181p) protein, β ² -amyloid1&E42, and β ² -amyloid1&E40 in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 192-5.	2.3	65
85	Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies. <i>Neurodegenerative Diseases</i> , 2007, 4, 366-375.	1.4	65
86	The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics. <i>Journal of Neural Transmission</i> , 2006, 113, 1075-1080.	2.8	64
87	Theory of mind and empathy in patients at an early stage of relapsing remitting multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1016-1022.	1.4	63
88	Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. <i>Biological Psychiatry</i> , 1997, 41, 1174-1180.	1.3	62
89	Homocysteine induces cell death of rat astrocytes in vitro. <i>Neuroscience Letters</i> , 2003, 347, 85-88.	2.1	61
90	Highly potent soluble amyloid- β ² seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> , 2014, 137, 2909-2915.	7.6	61

#	ARTICLE	IF	CITATIONS
91	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	7.9	61
92	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnesic mild cognitive impairment (MCI). <i>Neurobiology of Aging</i> , 2017, 53, 1-10.	3.1	59
93	CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Neural Transmission</i> , 2006, 113, 1771-1778.	2.8	58
94	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	27.8	58
95	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 84.	6.2	58
96	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
97	Minor neuropsychological deficits in patients with subjective cognitive decline. <i>Neurology</i> , 2020, 95, e1134-e1143.	1.1	58
98	Oxidative stress and an altered methionine metabolism in alcoholism. <i>Neuroscience Letters</i> , 2000, 293, 171-174.	2.1	57
99	Neurochemical dementia diagnostics: State of the art and research perspectives. <i>Proteomics</i> , 2008, 8, 1292-1301.	2.2	57
100	ABC Transporters Are Key Players in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 463-485.	2.6	57
101	Unchanged Survival Rates of 14-3-3 β Knockout Mice after Inoculation with Pathological Prion Protein. <i>Molecular and Cellular Biology</i> , 2005, 25, 1339-1346.	2.3	56
102	Structural Brain Alterations Associated With Schizophrenia Preceded by Conduct Disorder: A Common and Distinct Subtype of Schizophrenia?. <i>Schizophrenia Bulletin</i> , 2013, 39, 1115-1128.	4.3	56
103	Blood-based neurochemical diagnosis of vascular dementia: a pilot study. <i>Journal of Neurochemistry</i> , 2007, 103, 467-474.	3.9	55
104	Methylphenidate-Induced Psychosis in Adult Attention-Deficit/Hyperactivity Disorder. <i>Clinical Neuropharmacology</i> , 2010, 33, 204-206.	0.7	55
105	Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. <i>Brain</i> , 2010, 133, 3093-3103.	7.6	55
106	β 2-Amyloid Peptide Variants in Brains and Cerebrospinal Fluid from Amyloid Precursor Protein (APP) Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2011, 286, 33747-33758.	3.4	53
107	The Role of Variation at APP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 377-387.	2.6	53
108	Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models. <i>Acta Neuropathologica</i> , 2015, 130, 713-729.	7.7	53

#	ARTICLE	IF	CITATIONS
109	An infrared sensor analysing label-free the secondary structure of the Aβ peptide in presence of complex fluids. <i>Journal of Biophotonics</i> , 2016, 9, 224-234.	2.3	53
110	Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. <i>Journal of Neural Transmission</i> , 2008, 115, 1651-1659.	2.8	52
111	Comparison of the Nasal Release of IL-4, IL-10, IL-17, CCL13/MCP-4, and CCL26/eotaxin-3 in Allergic Rhinitis during Season and after Allergen Challenge. <i>American Journal of Rhinology and Allergy</i> , 2013, 27, 266-272.	2.0	52
112	A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. <i>Acta Neuropathologica Communications</i> , 2015, 3, 19.	5.2	52
113	Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides. <i>Neurobiology of Disease</i> , 2015, 73, 24-35.	4.4	52
114	Mismatch Negativity Latency and Cognitive Function in Schizophrenia. <i>PLoS ONE</i> , 2014, 9, e84536.	2.5	52
115	Genome-Wide Association Study of Vascular Dementia. <i>Stroke</i> , 2012, 43, 315-319.	2.0	51
116	Electrophoretic separation of amyloid β peptides in plasma. <i>Electrophoresis</i> , 2004, 25, 3336-3343.	2.4	50
117	Memantine Pharmacotherapy. <i>Clinical Pharmacokinetics</i> , 2007, 46, 599-612.	3.5	50
118	High-Fat Diet Induced Isoform Changes of the Parkinson's Disease Protein DJ-1. <i>Journal of Proteome Research</i> , 2014, 13, 2339-2351.	3.7	50
119	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.	0.8	50
120	Association of SORL1 gene variants with Alzheimer's disease. <i>Brain Research</i> , 2009, 1264, 1-6.	2.2	49
121	HUPO Brain Proteome Project: Summary of the pilot phase and introduction of a comprehensive data reprocessing strategy. <i>Proteomics</i> , 2006, 6, 4890-4898.	2.2	47
122	Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: Evidence for novel Aβ species. <i>Proteomics</i> , 2007, 7, 3815-3820.	2.2	47
123	Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. <i>Journal of Neural Transmission</i> , 2012, 119, 805-813.	2.8	47
124	Genetic interaction of <i>PICALM</i> and <i>APOE</i> is associated with brain atrophy and cognitive impairment in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S269-76.	0.8	47
125	A longitudinal approach to biological psychiatric research: The PsyCourse study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 89-102.	1.7	47
126	Bright basal ganglia in T1-weighted magnetic resonance images are frequent in patients with portal vein thrombosis without liver cirrhosis and not suggestive of hepatic encephalopathy. <i>Journal of Hepatology</i> , 1998, 29, 443-449.	3.7	46

#	ARTICLE	IF	CITATIONS
127	Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 244-250.	1.8	46
128	Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid- β 38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 37-44.	1.5	46
129	German Validation of the Conners Adult ADHD Rating Scale—Self-Report. <i>Journal of Attention Disorders</i> , 2013, 17, 690-698.	2.6	46
130	SUCLG2 identified as both a determinant of CSF A β 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	2.9	45
131	Neural Mechanisms Underlying Affective Theory of Mind in Violent Antisocial Personality Disorder and/or Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, 1229-1239.	4.3	45
132	Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 129-143.	3.2	45
133	The metalloprotease ADAMTS4 generates N-truncated A β 42 species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 239-257.	7.7	44
134	Kinetics of Serum Neuron-Specific Enolase and Prolactin in Patients After Single Epileptic Seizures. <i>Epilepsia</i> , 1999, 40, 713-718.	5.1	43
135	Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. <i>Brain Research</i> , 2005, 1052, 156-162.	2.2	43
136	Influence of SORL1 gene variants: Association with CSF amyloid- β products in probable Alzheimer's disease. <i>Neuroscience Letters</i> , 2008, 440, 68-71.	2.1	43
137	Tyr687 dependent APP endocytosis and abeta production. <i>Journal of Molecular Neuroscience</i> , 2007, 32, 1-8.	2.3	42
138	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. <i>PLoS ONE</i> , 2014, 9, e100812.	2.5	41
139	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 433-441.	2.6	41
140	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. <i>Neurology</i> , 2015, 84, 1261-1268.	1.1	41
141	Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 9, 100154.	2.5	41
142	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	6.2	40
143	A β and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 257-263.	2.4	40
144	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.	7.7	40

#	ARTICLE	IF	CITATIONS
145	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldtâ€“Jakob disease. <i>Proteomics</i> , 2010, 10, 81-89.	2.2	39
146	Microchip Electrophoresis Profiling of A β Peptides in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease. <i>Analytical Chemistry</i> , 2010, 82, 7611-7617.	6.5	39
147	Multidimensional plasma protein separation technique for identification of potential Alzheimerâ€™s disease plasma biomarkers: a pilot study. <i>Journal of Neural Transmission</i> , 2012, 119, 779-788.	2.8	39
148	A two-step immunoassay for the simultaneous assessment of A β 238, A β 240 and A β 242 in human blood plasma supports the A β 242/A β 240 ratio as a promising biomarker candidate of Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 121.	6.2	39
149	An Investigation of Psychosis Subgroups With Prognostic Validation and Exploration of Genetic Underpinnings. <i>JAMA Psychiatry</i> , 2020, 77, 523.	11.0	39
150	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. <i>Methods</i> , 2008, 44, 289-298.	3.8	38
151	An Open Trial of Gabapentin in Acute Alcohol Withdrawal Using an Oral Loading Protocol. <i>Alcohol and Alcoholism</i> , 2010, 45, 143-145.	1.6	38
152	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. <i>Human Brain Mapping</i> , 2016, 37, 2114-2132.	3.6	38
153	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. <i>NeuroImage</i> , 2020, 218, 116932.	4.2	38
154	Decreased circulating CD34+ stem cells in early Alzheimer's disease: evidence for a deficient hematopoietic brain support?. <i>Molecular Psychiatry</i> , 2006, 11, 1113-1115.	7.9	37
155	The impact of alcohol dependence on social brain function. <i>Addiction Biology</i> , 2013, 18, 109-120.	2.6	37
156	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinsonâ€™s Disease Dementia. <i>PLoS ONE</i> , 2012, 7, e48783.	2.5	37
157	Memantine in Moderate-to-Severe Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2003, 349, 609-610.	27.0	36
158	Reduced CSF carboxyterminally truncated A β peptides in frontotemporal lobe degenerations. <i>Journal of Neural Transmission</i> , 2007, 114, 621-628.	2.8	36
159	Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. <i>Neuroscience Letters</i> , 1998, 240, 171-173.	2.1	35
160	Genetic variation at the <i>CELFI</i> (CUGBP, elavâ€™like family member 1 gene) locus is genomeâ€™wide associated with Alzheimer's disease and obesity. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014, 165, 283-293.	1.7	35
161	Factors Responsible for Plasma β -Amyloid Accumulation in Chronic Kidney Disease. <i>Molecular Neurobiology</i> , 2016, 53, 3136-3145.	4.0	35
162	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimerâ€™s disease based on multicenter diffusion tensor imaging. <i>Journal of Neurology</i> , 2019, 266, 2465-2474.	3.6	35

#	ARTICLE	IF	CITATIONS
163	Analysis of Amino-Terminal Variants of Amyloid- β Peptides by Capillary Isoelectric Focusing Immunoassay. <i>Analytical Chemistry</i> , 2013, 85, 8142-8149.	6.5	34
164	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	3.1	34
165	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. <i>Human Brain Mapping</i> , 2015, 36, 3516-3527.	3.6	34
166	N-truncated A β peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 80.	6.2	34
167	Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	2.6	34
168	Increase in β -Amyloid Levels in Cerebrospinal Fluid of Children with Down Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 369-374.	1.5	33
169	Non-pharmacologic prevention of Alzheimer's disease: nutritional and life-style risk factors. <i>Journal of Neural Transmission</i> , 2007, 114, 1187-1197.	2.8	33
170	Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. <i>Neuroscience Letters</i> , 2014, 561, 41-45.	2.1	33
171	Tyrosine 687 Phosphorylated Alzheimer's Amyloid Precursor Protein Is Retained Intracellularly and Exhibits a Decreased Turnover Rate. <i>Neurodegenerative Diseases</i> , 2007, 4, 78-87.	1.4	32
172	The Effects of Acute Tryptophan Depletion on Reactive Aggression in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) and Healthy Controls. <i>PLoS ONE</i> , 2012, 7, e32023.	2.5	32
173	Analysis of Amyloid- β Peptides in Cerebrospinal Fluid Samples by Capillary Electrophoresis Coupled with LIF Detection. <i>Analytical Chemistry</i> , 2011, 83, 1696-1703.	6.5	31
174	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
175	Statin treatment and a disease-specific pattern of β -amyloid peptides in Alzheimer's disease. <i>Experimental Brain Research</i> , 2005, 164, 205-214.	1.5	30
176	Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 255-262.	2.6	29
177	Development of a magnetic immunosorbent for on-chip preconcentration of amyloid β isoforms: Representatives of Alzheimer's disease biomarkers. <i>Biomicrofluidics</i> , 2012, 6, 024126.	2.4	29
178	Association of systemic inflammation markers with the presence and extent of coronary artery calcification. <i>Cytokine</i> , 2012, 57, 251-257.	3.2	29
179	Deposition of C-terminally truncated A β species A β 37 and A β 39 in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica Communications</i> , 2016, 4, 24.	5.2	29
180	Prediction and Early Detection of Alzheimer's Dementia: Professional Disclosure Practices and Ethical Attitudes. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 145-155.	2.6	29

#	ARTICLE	IF	CITATIONS
181	A microRNA signature that correlates with cognition and is a target against cognitive decline. <i>EMBO Molecular Medicine</i> , 2021, 13, e13659.	6.9	29
182	Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. <i>Metabolic Brain Disease</i> , 1999, 14, 239-251.	2.9	28
183	Structural Design, Solidâ€Phase Synthesis and Activity of Membraneâ€Anchored Î²â€Secretase Inhibitors on AÎ² Generation from Wildâ€Type and Swedishâ€Mutant APP. <i>Chemistry - A European Journal</i> , 2010, 16, 14412-14423.	3.3	28
184	Multiplex immunoassay measurement of amyloid-Î² ₄₂ to amyloid-Î² ₄₀ ratio in plasma discriminates between dementia due to Alzheimerâ€™s disease and dementia not due to Alzheimerâ€™s disease. <i>Experimental Brain Research</i> , 2018, 236, 1241-1250.	1.5	28
185	Psychiatric aspects of portal-systemic encephalopathy. <i>Metabolic Brain Disease</i> , 1998, 13, 379-389.	2.9	27
186	Differential processing and secretion of AÎ² peptides and sAPPÎ± in human platelets is regulated by thrombin and prostaglandine 2. <i>Neurobiology of Aging</i> , 2009, 30, 1552-1562.	3.1	27
187	Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2011, 8, 893-901.	1.4	27
188	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	3.1	27
189	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
190	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. <i>Scientific Reports</i> , 2017, 7, 9529.	3.3	27
191	Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimerâ€™s Disease Discrimination: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 391-405.	2.6	27
192	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimerâ€™s disease. <i>Neuron</i> , 2022, 110, 1009-1022.e4.	8.1	27
193	CSF Amyloid-Î² Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 383-391.	2.6	26
194	The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms. <i>Clinical and Translational Allergy</i> , 2012, 2, 13.	3.2	26
195	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 782-790.	2.4	26
196	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
197	Serotonin Transporters in the Rat Frontal Cortex: Lack of Circadian Rhythmicity but Downâ€Regulation by Food Restriction. <i>Journal of Neurochemistry</i> , 1996, 67, 656-661.	3.9	25
198	Neuroleptic drugs in the human brain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 274-280.	3.2	25

#	ARTICLE	IF	CITATIONS
199	CSF amyloid β 1 β 38 and 1 β 42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1548-1556.	1.6	25
200	Combined treatment with memantine and galantamine \pm CR compared with galantamine \pm CR only in antidementia drug naïve patients with mild to moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 198-204.	3.7	25
201	Masturbation Experiences of Swedish Senior High School Students: Gender Differences and Similarities. <i>Journal of Sex Research</i> , 2017, 54, 631-641.	2.5	25
202	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. <i>Alzheimer's and Dementia</i> , 2023, 19, 487-497.	0.8	25
203	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. <i>Scientific Reports</i> , 2016, 6, 26145.	3.3	24
204	The genetic relationship between educational attainment and cognitive performance in major psychiatric disorders. <i>Translational Psychiatry</i> , 2019, 9, 210.	4.8	24
205	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. <i>Magnetic Resonance Imaging</i> , 2021, 76, 108-115.	1.8	24
206	The Latent Dementia Phenotype \hat{I} is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 547-560.	2.6	23
207	The increase in medial prefrontal glutamate/glutamine concentration during memory encoding is associated with better memory performance and stronger functional connectivity in the human medial prefrontal-thalamus-hippocampus network. <i>Human Brain Mapping</i> , 2018, 39, 2381-2390.	3.6	23
208	Violent aggression predicted by multiple pre-adult environmental hits. <i>Molecular Psychiatry</i> , 2019, 24, 1549-1564.	7.9	23
209	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 8.	6.2	23
210	Plasma A β 42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnesic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 37-48.	2.6	23
211	Clinico-genetic findings in 509 frontotemporal dementia patients. <i>Molecular Psychiatry</i> , 2021, 26, 5824-5832.	7.9	23
212	Polysomnographic findings in five adult patients with pituitary insufficiency before and after cessation of human growth hormone replacement therapy. <i>Clinical Endocrinology</i> , 2002, 56, 805-810.	2.4	22
213	Region specific distribution of levomepromazine in the human brain. <i>Journal of Neural Transmission</i> , 2006, 113, 387-397.	2.8	22
214	Antidepressant drugs modulate growth factors in cultured cells. <i>BMC Pharmacology</i> , 2008, 8, 6.	0.4	22
215	Cerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 256-265.	1.5	22
216	Stability of amyloid β peptides in plasma and serum. <i>Electrophoresis</i> , 2012, 33, 445-450.	2.4	22

#	ARTICLE	IF	CITATIONS
217	A comprehensive score reflecting memory-related <scp>fMRI</scp> activations and deactivations as potential biomarker for neurocognitive aging. <i>Human Brain Mapping</i> , 2021, 42, 4478-4496.	3.6	22
218	Quantification of amyloid-beta 40 in cerebrospinal fluid. <i>Journal of Immunological Methods</i> , 2009, 348, 57-66.	1.4	21
219	Phagocytosis and LPS alter the maturation state of β 2-amyloid precursor protein and induce different β 2 peptide release signatures in human mononuclear phagocytes. <i>Journal of Neuroinflammation</i> , 2010, 7, 59.	7.2	21
220	Impaired empathy but no theory of mind deficits in adult attention deficit hyperactivity disorder. <i>Brain and Behavior</i> , 2019, 9, e01401.	2.2	21
221	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 191.	6.2	21
222	Molecular Biology of Alzheimer's Dementia and Its Clinical Relevance to Early Diagnosis and New Therapeutic Strategies. <i>Gerontology</i> , 2001, 47, 65-71.	2.8	20
223	Lithium Decreases Secretion of β 1-42 and C-Truncated Species β 1-37/38/39/40 in Chicken Telencephalic Cultures but Specifically Increases Intracellular β 1-38. <i>Neurodegenerative Diseases</i> , 2004, 1, 236-241.	1.4	20
224	Light-induced exocytosis in cell development and differentiation. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 1393-1406.	2.6	20
225	Immune complexes of auto-antibodies against β 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. <i>Molecular Psychiatry</i> , 2007, 12, 601-610.	7.9	20
226	Spontaneous magnetoencephalographic activity in patients with obsessive-compulsive disorder. <i>Brain Research</i> , 2007, 1129, 200-205.	2.2	20
227	Perception of affective prosody in patients at an early stage of relapsing/remitting multiple sclerosis. <i>Journal of Neuropsychology</i> , 2013, 7, 91-106.	1.4	20
228	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. <i>Bipolar Disorders</i> , 2019, 21, 68-75.	1.9	20
229	Comparison between amyloid-PET and CSF amyloid- β 2 biomarkers in a clinical cohort with memory deficits. <i>Clinica Chimica Acta</i> , 2019, 492, 62-68.	1.1	20
230	Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression. <i>Neuroscience Letters</i> , 2009, 463, 26-30.	2.1	19
231	Modulatory effects of neuropsychopharmaca on intracellular pH of hippocampal neurones <i>in vitro</i>. <i>British Journal of Pharmacology</i> , 2010, 159, 474-483.	5.4	19
232	Spot quantification in two dimensional gel electrophoresis image analysis: comparison of different approaches and presentation of a novel compound fitting algorithm. <i>BMC Bioinformatics</i> , 2014, 15, 181.	2.6	19
233	Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples. <i>Proteomics</i> , 2014, 14, 1954-1962.	2.2	19
234	Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. <i>BMC Psychiatry</i> , 2019, 19, 393.	2.6	19

#	ARTICLE	IF	CITATIONS
235	The Role of Cathepsin B in the Degradation of A β 2 and in the Production of A β 2 Peptides Starting With Ala2 in Cultured Astrocytes. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 615740.	2.9	19
236	Creutzfeldt-Jakob disease and oxidative stress. <i>Acta Neurologica Scandinavica</i> , 2000, 101, 332-334.	2.1	18
237	Memantine fails to facilitate partial cigarette deprivation in smokers – no role of Memantine in the treatment of nicotine dependency?. <i>Journal of Neural Transmission</i> , 2007, 114, 351-357.	2.8	18
238	Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 613-622.	2.6	18
239	Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores – development of potential agents for the treatment of Alzheimer's disease. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 8216.	2.8	18
240	Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid β 2 peptides. <i>Proteomics - Clinical Applications</i> , 2012, 6, 163-169.	1.6	18
241	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	2.6	18
242	Predicting and Tracking Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 3-14.	2.6	18
243	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. <i>Clinica Chimica Acta</i> , 2019, 491, 81-84.	1.1	18
244	Differential diagnosis of neurodegenerative diseases with special emphasis on Creutzfeldt-Jakob disease. <i>Restorative Neurology and Neuroscience</i> , 2003, 21, 191-209.	0.7	18
245	Combined Analysis of CSF Tau, A β 42, A β 1-42% and A β 1-40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-7.	2.0	17
246	Pre-aggregated A β 1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application. <i>Molecular and Cellular Biochemistry</i> , 2011, 349, 169-177.	3.1	17
247	Small cisterno-lumbar gradient of phosphorylated Tau protein in geriatric patients with suspected normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2016, 13, 15.	5.0	17
248	Validation of soluble amyloid β 2 precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016, 137, 112-121.	3.9	17
249	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 610-618.	2.4	17
250	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. <i>Cortex</i> , 2019, 117, 33-40.	2.4	17
251	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers – results from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 131.	6.2	17
252	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2020, 28, 102495.	2.7	17

#	ARTICLE	IF	CITATIONS
253	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-12.	2.0	16
254	Aerobic Activity in the Healthy Elderly Is Associated with Larger Plasticity in Memory Related Brain Structures and Lower Systemic Inflammation. <i>Frontiers in Aging Neuroscience</i> , 2016, 08, 319.	3.4	16
255	Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 339-348.	2.8	16
256	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 40-48.	1.9	16
257	Extensive craving in high dose zolpidem dependency. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 591-592.	4.8	15
258	Different CSF β -amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. <i>Journal of Neural Transmission</i> , 2011, 118, 691-697.	2.8	15
259	Neurochemical biomarkers in Alzheimer's disease and related disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 335-348.	3.5	15
260	Occipital event-related potentials to addiction-related stimuli in detoxified patients with alcohol dependence, and their association with three-month relapse. <i>BMC Psychiatry</i> , 2016, 16, 74.	2.6	15
261	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 455-465.	2.6	15
262	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2021, 29, 102533.	2.7	15
263	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 626974.	3.4	15
264	β peptide ⁴² , Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. <i>Neuroscience Letters</i> , 2002, 333, 33-36.	2.1	14
265	Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid- β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 691-705.	2.6	14
266	Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 203-212.	2.6	14
267	The Role of Proopiomelanocortin and β -Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review. <i>Frontiers in Psychiatry</i> , 2019, 10, 834.	2.6	14
268	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment" data from the Dementia Competence Network. <i>Journal of Neural Transmission</i> , 2022, 129, 477-486.	2.8	14
269	Quantification of the electroencephalographic theta/alpha ratio for the assessment of portal-systemic encephalopathy following implantation of transjugular intrahepatic portosystemic stent shunt (TIPSS). <i>Metabolic Brain Disease</i> , 2002, 17, 19-28.	2.9	13
270	Follow-Up Investigations of Tau Protein and S-100B Levels in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 376-382.	1.5	13

#	ARTICLE	IF	CITATIONS
271	Adherence-dependent shifts in the patterns of β^2 -amyloid peptides secreted by human mononuclear phagocytes. <i>Brain, Behavior, and Immunity</i> , 2008, 22, 1044-1048.	4.1	13
272	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 389-401.	2.6	13
273	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 27.	6.2	13
274	Cardiovascular and metabolic comorbidities in patients with Alzheimer's disease and vascular dementia compared to a psychiatric control cohort. <i>Psychogeriatrics</i> , 2018, 18, 393-401.	1.2	13
275	Neural cell-surface and intracellular autoantibodies in patients with cognitive impairment from a memory clinic cohort. <i>Journal of Neural Transmission</i> , 2021, 128, 357-369.	2.8	13
276	The role of environmental stress and DNA methylation in the longitudinal course of bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 9.	2.2	13
277	Novel Exosome Biomarker Candidates for Alzheimer's Disease Unravelling Through Mass Spectrometry Analysis. <i>Molecular Neurobiology</i> , 2022, 59, 2838-2854.	4.0	13
278	Recurrent systemic infections with <i>Streptococcus pneumoniae</i> do not aggravate the course of experimental neurodegenerative diseases. <i>Journal of Neuroscience Research</i> , 2010, 88, 1124-1136.	2.9	12
279	A quantitative CE method to analyse tau protein isoforms using coated fused silica capillaries. <i>Journal of Separation Science</i> , 2010, 33, 1090-1098.	2.5	12
280	Intrathecal IgG Synthesis in Patients with Alterations in the Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1199-1203.	2.6	12
281	Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-9.	2.0	12
282	Aminoterminally Truncated and Oxidized Amyloid- β^2 Peptides in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 809-816.	2.6	12
283	An ATR-FTIR Sensor Unraveling the Drug Intervention of Methylene Blue, Congo Red, and Berberine on Human Tau and $A\beta^2$. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 710-714.	2.8	12
284	Putative Dementia Cases Fluctuate as a Function of Mini-Mental State Examination Cut-Off Points. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 157-167.	2.6	12
285	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 340.	3.4	12
286	Development and Technical Validation of an Immunoassay for the Detection of APP669-711 ($A\beta^{3-40}$) in Biological Samples. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6564.	4.1	12
287	Exosomal $A\beta^2$ -Binding Proteins Identified by <i>in Silico</i> Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3933.	4.1	12
288	Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 94.	6.2	12

#	ARTICLE	IF	CITATIONS
289	Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. <i>Cerebral Cortex</i> , 2021, 31, 4901-4915.	2.9	12
290	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1267-1282.	2.6	12
291	Proteomic Analysis of the Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 22-28.	1.5	11
292	New pathways of increased cardiovascular risk in depression: A pilot study on the association of high-sensitivity C-reactive protein with pro-atherosclerotic markers in patients with depression. <i>Journal of Affective Disorders</i> , 2013, 146, 420-425.	4.1	11
293	Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands. <i>Electrophoresis</i> , 2015, 36, 355-362.	2.4	11
294	CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	3.1	11
295	Pre-Analytical Sampling and Storage Conditions of Amyloid- β 2 Peptides in Venous and Capillary Blood. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 529-535.	2.6	11
296	Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. <i>Neurology</i> , 2021, 96, e1358-e1368.	1.1	11
297	Polygenic risk scores across the extended psychosis spectrum. <i>Translational Psychiatry</i> , 2021, 11, 600.	4.8	11
298	Neurochemical dementia diagnostics: assays in CSF and blood. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 44-49.	3.2	10
299	Association of N-Acetylaspartate and Cerebrospinal Fluid A β 242 in Dementia. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 393-399.	2.6	10
300	N-Terminal Truncated A β 24-42 Is a Substrate for Neprilysin Degradation <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Alzheimer's Disease</i> , 2019, 67, 849-858.	2.6	10
301	Higher Level of Mismatch in <i>APOE</i> ϵ 4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid. <i>ASN Neuro</i> , 2019, 11, 175909141984552.	2.7	10
302	Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. <i>NeuroImage: Clinical</i> , 2020, 25, 102112.	2.7	10
303	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. <i>Cortex</i> , 2021, 140, 66-79.	2.4	10
304	Elevated levels of serum S100 beta protein in scrapie hamsters. <i>Journal of NeuroVirology</i> , 1998, 4, 572-573.	2.1	9
305	Late Increase of Serum S100 β Protein Levels in Hamsters after Oral or Intraperitoneal Infection with Scrapie. <i>Journal of Infectious Diseases</i> , 1999, 180, 518-520.	4.0	9
306	SHOULD ASPIRIN BE DISCONTINUED FOR DIAGNOSTIC LUMBAR PUNCTURE?. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 181-182.	2.6	9

#	ARTICLE	IF	CITATIONS
307	Distinct fractional A β 2 release patterns in human mononuclear phagocytes. <i>Journal of Neuroimmunology</i> , 2009, 206, 1-4.	2.3	9
308	ERK2 is Increased in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 119-128.	2.6	9
309	N-Truncated A β 2-X Starting with Position Two in Sporadic Alzheimer's Disease Cases and Two Alzheimer Mouse Models. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 101-110.	2.6	9
310	The effect of auditory and visual training on the mismatch negativity in schizophrenia. <i>International Journal of Psychophysiology</i> , 2016, 102, 47-54.	1.0	9
311	Association of Plasma β -Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease. <i>Molecular Neurobiology</i> , 2017, 54, 7194-7203.	4.0	9
312	The influence of religious activity and polygenic schizophrenia risk on religious delusions in schizophrenia. <i>Schizophrenia Research</i> , 2019, 210, 255-261.	2.0	9
313	Case Report: Anti-flotillin 1/2 Autoantibody-Associated Atypical Dementia. <i>Frontiers in Psychiatry</i> , 2021, 12, 626121.	2.6	9
314	The N -methyl- d -aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue. <i>Acta Neuropathologica</i> , 1999, 98, 85-90.	7.7	8
315	Systemic and splanchnic endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS). <i>Liver International</i> , 2000, 20, 60-65.	3.9	8
316	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 109-113.	2.6	8
317	No Clear Association between Impaired Short-Term or Working Memory Storage and Time Reproduction Capacity in Adult ADHD Patients. <i>PLoS ONE</i> , 2015, 10, e0133714.	2.5	8
318	Solid β -Phase Synthesis and Characterization of N-Terminally Elongated A β 3 Peptides. <i>Chemistry - A European Journal</i> , 2016, 22, 8685-8693.	3.3	8
319	P3 β : A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1352.	0.8	8
320	Biomarker Matrix to Track Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 49-58.	2.6	8
321	Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients. <i>Human Psychopharmacology</i> , 2021, 36, e2800.	1.5	8
322	Glutamine synthetase in experimental meningitis: increased ratio of the subunits 3 and 2 may indicate enhanced activity. <i>Clinica Chimica Acta</i> , 2000, 292, 1-12.	1.1	7
323	Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein. <i>Neurodegenerative Diseases</i> , 2009, 6, 1-8.	1.4	7
324	PLASMA HOMOCYSTEINE AND CEREBROSPINAL FLUID NEURODEGENERATION BIOMARKERS IN MILD COGNITIVE IMPAIRMENT AND DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 737-739.	2.6	7

#	ARTICLE	IF	CITATIONS
325	Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 2667-2672.	5.5	7
326	Continuity of treatment with benzodiazepines in dementia patients. <i>International Clinical Psychopharmacology</i> , 2018, 33, 282-289.	1.7	7
327	Study Protocol: Does an Acute Intervention of High-Intensity Physical Exercise Followed by a Brain Training Video Game Have Immediate Effects on Brain Activity of Older People During Stroop Task in fMRI? A Randomized Controlled Trial With Crossover Design. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 260.	3.4	7
328	A genome-wide association study of the longitudinal course of executive functions. <i>Translational Psychiatry</i> , 2021, 11, 386.	4.8	7
329	Cerebrospinal Fluid Total Tau Protein Correlates With Longitudinal, Progressing Cognitive Dysfunction in Anti-Neural Autoantibody-Associated Dementia and Alzheimer's Disease: A Case-Control Study. <i>Frontiers in Immunology</i> , 2022, 13, 837376.	4.8	7
330	Distributions of A β 42 and A β 42/40 in the Cerebrospinal Fluid in View of the Probability Theory. <i>Diagnostics</i> , 2021, 11, 2372.	2.6	7
331	Creutzfeldt-Jakob Disease and Homocysteine Levels in Plasma and Cerebrospinal Fluid. <i>Gerontology</i> , 2005, 51, 142-144.	2.8	6
332	Confirmation rate of blinded 99mTc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1111-1114.	2.8	6
333	KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. <i>Brain Sciences</i> , 2021, 11, 89.	2.3	6
334	Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry. <i>Journal of Neural Transmission</i> , 2021, 128, 735-747.	2.8	6
335	Detection and quantification of A β 3 β 40 (APP669 Δ E711) in cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2022, 160, 578-589.	3.9	6
336	Increased transcranial magnetic motor threshold after ECT. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002, 252, 250-252.	3.2	5
337	Pharmacokinetic Characterization of Amantadine in Human Brain Tissue. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 693-695.	2.0	5
338	Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay. <i>Scientific Reports</i> , 2015, 5, 12767.	3.3	5
339	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. <i>Epigenomics</i> , 2016, 8, 593-598.	2.1	5
340	Methylene Blue (Tetramethylthionine Chloride) Influences the Mobility of Adult Neural Stem Cells: A Potentially Novel Therapeutic Mechanism of a Therapeutic Approach in the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 531-540.	2.6	5
341	Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1137-1148.	2.6	5
342	Mild Amnestic Cognitive Impairment and Depressive Symptoms in Autoimmune Encephalitis Associated with Serum Anti-Neurexin-3 β Autoantibodies. <i>Brain Sciences</i> , 2021, 11, 673.	2.3	5

#	ARTICLE	IF	CITATIONS
343	Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and inÂvitro evaluation of a radioactive tracer for imaging. <i>European Journal of Medicinal Chemistry</i> , 2022, 232, 114138.	5.5	5
344	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 545-555.	2.6	5
345	Case Report: Alzheimer's Dementia Associated With Cerebrospinal Fluid Neurochondrin Autoantibodies. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	5
346	Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics. <i>Expert Review of Proteomics</i> , 2008, 5, 153-156.	3.0	4
347	Serum albumin correlates with affective prosody in adult males with attention-deficit hyperactivity disorder. <i>Psychiatry Research</i> , 2014, 217, 198-201.	3.3	4
348	[P4â€™157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€™OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1319.	0.8	4
349	A rare heterozygous <i>TREM2</i> coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. <i>Human Mutation</i> , 2020, 41, 169-181.	2.5	4
350	Sexual dysfunction in patients with adult attention deficit hyperactivity disorder: A pilot study. <i>Canadian Journal of Human Sexuality</i> , 2021, 30, 106-113.	1.6	4
351	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12223.	2.4	4
352	Current clinical practice of electroconvulsive therapy and repetitive transcranial magnetic stimulation in psychiatry, a German sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 181-190.	3.2	4
353	Predicting disease progression in behavioral variant frontotemporal dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12262.	2.4	4
354	Prevalence of Anti-neural Autoantibodies in a Psychiatric Patient Cohort-Paradigmatic Application of Criteria for Autoimmune-Based Psychiatric Syndromes. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	4
355	Identification of risk factors for delirium, cognitive decline, and dementia after cardiac surgery (FINDERIâ€™find delirium risk factors): a study protocol of a prospective observational study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	1.7	4
356	A Comparison of Operational Definitions for Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1663-1678.	2.6	4
357	Different binding pattern of antibodies to prion protein on lymphocytes from patients with sporadic Creutzfeldtâ€™Jakob disease. <i>Neuroscience Letters</i> , 2003, 343, 29-32.	2.1	3
358	AIDS dementia complex and Hashimoto encephalopathy in a senescent woman. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 1267-1268.	2.7	3
359	Toward a Successful Clinical Neuroproteomics The 11th HUPO Brain Proteome Project Workshop 3 March, 2009, Kolybari, Greece. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1012-1016.	1.6	3
360	Plasma Amyloidâ€™Beta</scp>Peptides in Acute Cerebral Ischemia: A Pilot Study. <i>Journal of Clinical Laboratory Analysis</i> , 2012, 26, 238-245.	2.1	3

#	ARTICLE	IF	CITATIONS
361	Cisterno-lumbar gradient of complement fractions in geriatric patients with suspected normal pressure hydrocephalus. <i>Clinica Chimica Acta</i> , 2018, 486, 1-7.	1.1	3
362	Claims Data Analysis on the Dispensing of Tricyclic Antidepressants Among Patients With Dementia in Germany. <i>Frontiers in Pharmacology</i> , 2019, 10, 841.	3.5	3
363	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. <i>Brain Research Bulletin</i> , 2020, 161, 13-20.	3.0	3
364	Catatonic Schizophrenia Associated With Cerebrospinal GAD65 Autoantibodies: Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2022, 13, 829058.	4.8	3
365	Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-2.	2.0	2
366	[P1â€“122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER'S DISEASE, AND NEURAL NETWORKS. <i>Alzheimer's and Dementia</i> , 2017, 13, P287.	0.8	2
367	Bacterial infections among patients with psychiatric disorders: Relation with hospital stay, age, and psychiatric diagnoses. <i>PLoS ONE</i> , 2018, 13, e0208458.	2.5	2
368	Mild Cognitive Impairment in Chronic Brain Injury Associated with Serum Anti-AP3B2 Autoantibodies: Report and Literature Review. <i>Brain Sciences</i> , 2021, 11, 1208.	2.3	2
369	Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-Î² in Human Blood Plasma. <i>Methods in Molecular Biology</i> , 2018, 1750, 111-124.	0.9	2
370	Impaired Verbal Memory Recall in Patients With Axonal Degeneration and Serum Glycine-Receptor Autoantibodiesâ€”Case Series. <i>Frontiers in Psychiatry</i> , 2021, 12, 778684.	2.6	2
371	Stability over time of scores on psychiatric rating scales, questionnaires and cognitive tests in healthy controls. <i>BJPsych Open</i> , 2022, 8, e55.	0.7	2
372	A novel longitudinal clustering approach to psychopathology across diagnostic entities in the hospital-based PsyCourse study. <i>Schizophrenia Research</i> , 2022, 244, 29-38.	2.0	2
373	Regional gene expression patterns are associated with taskâ€“specific brain activation during reward and emotion processing measured with functional <sc>MRI</sc>. <i>Human Brain Mapping</i> , 2022, 43, 5266-5280.	3.6	2
374	Unaltered apoptotic behaviour of mononuclear cells from patients with sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2001, 248, 690-694.	3.6	1
375	Histologically confirmed amyloid deposition and low CSF AÎ² 42 in a cognitively normal subject. <i>Journal of Neurology</i> , 2007, 254, 970-971.	3.6	1
376	A method to prevent cross contamination during 2â€“DE by Î²â€“amyloid peptides. <i>Proteomics</i> , 2010, 10, 3539-3543.	2.2	1
377	[P2â€“390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P779.	0.8	1
378	P4â€“068: LEVELS OF THE ASTROCYTEâ€“DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1458.	0.8	1

#	ARTICLE	IF	CITATIONS
379	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSF A β pathology: Data from the DELCODE Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044741.	0.8	1
380	<i>Demenz.</i> , 2017, , 1377-1465.		1
381	Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infection. <i>BJPsych Open</i> , 2021, 7, e188.	0.7	1
382	Unemployment and Health – a Public Health Perspective: Model Project. <i>Deutsches A&#x0308;rzteblatt International</i> , 2008, 105, 127; author reply 127.	0.9	1
383	Case Report: Semantic Variant of Primary Progressive Aphasia Associated With Anti-Glial Fibrillary Acid Protein Autoantibodies. <i>Frontiers in Immunology</i> , 2021, 12, 760021.	4.8	1
384	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
385	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
386	Quantification of Changes in Electroencephalographic Power Spectra in a Patient with Budd-Chiari-Syndrome after Implantation of a Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS). <i>Metabolic Brain Disease</i> , 2005, 20, 1-6.	2.9	0
387	Creating a Human Brain Proteome Atlas - 13th HUPO BPP Workshop March 30-31, 2010, Ochang, Korea. <i>Proteomics</i> , 2011, 11, 2759-2762.	2.2	0
388	P4-174: Evaluation of Cutoff Values For Fully Automated Hippocampus Volumetry With Fsl-First For Prediction Of Alzheimer's Disease Dementia In Mci Subjects. , 2016, 12, P1084-P1085.		0
389	Gearing up for the Pearl Anniversary: AGNP Set to Hold its 30th Meeting in Munich October 4-6, 2017. Overview and Abstracts. <i>Pharmacopsychiatry</i> , 2017, 50, 211-212.	3.3	0
390	[P2-074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. <i>Alzheimer's and Dementia</i> , 2017, 13, P634.	0.8	0
391	[P3-164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE C β 2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P997.	0.8	0
392	[P3-393]: ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER'S DISEASE BASED ON MULTICENTER RESTING-STATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1112.	0.8	0
393	[P4-139]: APPLICATION OF THE A/T/N BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1310.	0.8	0
394	[P4-248]: QUALITY ASSURANCE IN DELCODE: A MULTICENTER NEUROIMAGING STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1372.	0.8	0
395	P1-379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P443.	0.8	0
396	P3-327: NEUROPSYCHIATRIC SYMPTOMS IN AT-RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1206.	0.8	0

#	ARTICLE	IF	CITATIONS
397	P2â€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.8	0
398	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.8	0
399	ICâ€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.8	0
400	ICâ€Pâ€163: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P137.	0.8	0
401	F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396.	0.8	0
402	P2â€447: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P888.	0.8	0
403	6 .Diagnostische Methoden. , 2018, , 187-352.		0
404	Cover Image, Volume 180B, Number 2, March 2019. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, i.	1.7	0
405	ICâ€Pâ€122: ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT RISK STAGES OF ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2019, 15, P101.	0.8	0
406	Prevalence of affective disorders and dementia in inflammatory polyarthropathies. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 247-252.	3.2	0
407	Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings. Aging Clinical and Experimental Research, 2020, 32, 809-815.	2.9	0
408	Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimer's Disease Dementia via Lead-Lag Analysis. Journal of Alzheimer's Disease, 2020, 76, 1005-1015.	2.6	0
409	Amygdalar nuclei and hippocampal subfields on MRI: Testâ€retest reliability of automated segmentation in old and young healthy volunteers. Alzheimer's and Dementia, 2020, 16, e040322.	0.8	0
410	Altered resting state activity associated with anosognosia in Alzheimer's clinical syndrome: Findings from the DELCODE study. Alzheimer's and Dementia, 2020, 16, e040416.	0.8	0
411	Awareness of cognitive decline and CSFâ€biomarkers in memory clinic patients: Results from the DELCODEâ€study. Alzheimer's and Dementia, 2020, 16, e044744.	0.8	0
412	The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2020, 16, e045349.	0.8	0
413	Demenz. , 2016, , 1-89.		0
414	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
415	Cost of illness of apathy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
416	Characterization of the NIA's Research Framework stage 2 in the longitudinal multicenter DELCODE study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
417	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimer's disease: The first step towards comprehensive artificial intelligence. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
418	Prediction of amyloid positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize number needed to screen. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
419	City Environment and Occurrence of Neural Autoantibodies in Psychiatric Patients. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	0